{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:06:39Z","timestamp":1784563599191,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.ejps.2005.02.006","type":"journal-article","created":{"date-parts":[[2005,3,19]],"date-time":"2005-03-19T23:18:26Z","timestamp":1111274306000},"page":"163-173","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic\u2013pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model"],"prefix":"10.1016","volume":"25","author":[{"given":"Lena E.","family":"Friberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia B.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Lindhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2005.02.006_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00001813-200111000-00005","article-title":"Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro","volume":"12","author":"Aleskog","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2005.02.006_bib2","unstructured":"Beal, S.L., Sheiner, L.B., 1992. NONMEM Users Guides, NONMEM project group, University of California, San Francisco."},{"key":"10.1016\/j.ejps.2005.02.006_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685732","article-title":"The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion","volume":"36","author":"Boddy","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2005.02.006_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01059269","article-title":"Enteric transport of chlordecone (Kepone) in the rat","volume":"9","author":"Bungay","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2005.02.006_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/53.3.661","article-title":"Breast tumor cell lines from pleural effusions","volume":"53","author":"Cailleau","year":"1974","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2005.02.006_bib6","first-page":"1","article-title":"Studies on coprophagy in experimental animals","volume":"42","author":"Ebino","year":"1993","journal-title":"Jikken Dobutsu"},{"key":"10.1016\/j.ejps.2005.02.006_bib7","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European\u2013Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2005.02.006_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J","article-title":"Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia","volume":"18","author":"Foley","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2005.02.006_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1023573429626","article-title":"Mechanistic models for myelosuppression","volume":"21","author":"Friberg","year":"2003","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2005.02.006_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2125.1999.00090.x","article-title":"A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients","volume":"48","author":"Hassan","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2005.02.006_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00001813-200101000-00005","article-title":"A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828","volume":"12","author":"Hassan","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2005.02.006_bib12","first-page":"1140","article-title":"Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action","volume":"299","author":"Hassan","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2005.02.006_bib13","series-title":"Contributions to Oncology, Relevance of Tumor Models for Anticancer Drug Development","first-page":"109","article-title":"The hollow fiber assay","author":"Hollingshead","year":"1999"},{"key":"10.1016\/j.ejps.2005.02.006_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(95)00254-4","article-title":"In vivo cultivation of tumor cells in hollow fibers","volume":"57","author":"Hollingshead","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.ejps.2005.02.006_bib15","first-page":"2843","article-title":"A phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2005.02.006_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002800000181","article-title":"Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats","volume":"46","author":"Jonsson","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2005.02.006_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose-an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejps.2005.02.006_bib18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.2600600618","article-title":"Pharmacodynamics of chemotherapeutic effects: dose\u2013time\u2013response relationships for phase-nonspecific agents","volume":"60","author":"Jusko","year":"1971","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2005.02.006_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01062346","article-title":"A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents","volume":"1","author":"Jusko","year":"1973","journal-title":"J. Pharmacokin. Biopharm."},{"key":"10.1016\/j.ejps.2005.02.006_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ddr.10353","article-title":"Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828","volume":"61","author":"Lindhagen","year":"2004","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejps.2005.02.006_bib21","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1208\/ps040442","article-title":"Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro","volume":"4","author":"Lobo","year":"2002","journal-title":"AAPS Pharm. Sci."},{"key":"10.1016\/j.ejps.2005.02.006_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0959-8049(00)00375-0","article-title":"Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells","volume":"37","author":"Martinsson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2005.02.006_bib23","first-page":"5263","article-title":"Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs","volume":"58","author":"Phillips","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2005.02.006_bib24","series-title":"Anticancer Drug Development Guide","first-page":"101","article-title":"Human tumor xenograft models in NCI drug development","author":"Plowman","year":"1997"},{"key":"10.1016\/j.ejps.2005.02.006_bib25","first-page":"2914","article-title":"An EORTC\/ECSG phase I study of CHS 828, a cyanoguanidine in patients with refractory solid tumors","volume":"42","author":"Ravaud","year":"2001","journal-title":"Proc. Am. Assoc. Cancer Rec."},{"key":"10.1016\/j.ejps.2005.02.006_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jxb\/10.2.290","article-title":"A flexible growth function for empirical use","volume":"10","author":"Richards","year":"1959","journal-title":"J. Exp. Bot."},{"key":"10.1016\/j.ejps.2005.02.006_bib27","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","article-title":"Predictive pharmacokinetic\u2013pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"64","author":"Simeoni","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2005.02.006_bib28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1989.7.9.1333","article-title":"A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer","volume":"7","author":"Slevin","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2005.02.006_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1042\/bst0090170","article-title":"Hepatic bile salt transport. A review of subcellular binding sites","volume":"9","author":"Strange","year":"1981","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejps.2005.02.006_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(98)00400-1","article-title":"Gastrointestinal transit of pellets in rats: effect of size and density","volume":"180","author":"Tuleu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2005.02.006_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1056-8719(99)00026-X","article-title":"Analysis of asymmetry of agonist concentration\u2013effect curves","volume":"41","author":"Van der Graaf","year":"1999","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2005.02.006_bib32","first-page":"5751","article-title":"CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo","volume":"59","author":"Vig Hjarnaa","year":"1999","journal-title":"Cancer Res."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098705000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098705000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:43:17Z","timestamp":1549309397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098705000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0928098705000667"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2005.02.006","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}